Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

VolitionRX Limited (VNRX)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
2.6100-0.2400 (-8.42%)
At close: 04:00PM EST
Advertisement
Sign in to post a message.
  • A
    Av
    Very interesting,with a deal in progress being imminent,the share price is continuing to slide.I wonder who would want to sell at these levels especially as it is common knowledge a Deal will be signed by years end.
  • D
    Damien
    I'm surprised last week's news hasn't propelled the stock higher!
  • K
    Karen
    why the run up today?
    Bullish
  • M
    Mike
    Check out Dr Tom Butera, new CEO of Volition's Vet business with the recently launched Dog Cancer screening test using VNRX' patented tech (to be used later down the line for humans).   He is coming from VCA Animal Hospitals, which is owned by Mars, who in turn operates the largest animal hospital network in the US.   His resume is legit if you do your DD.  People love their dogs, and as people replace kids with pets (bad idea society!), the desire to prolong a dog's life will only increase in the future.

    You could buy this one for the dog testing alone and be looking at a 5 bagger.  If you're willing to hold?  Who knows, but massive upside it would seem.  Doesn't hurt that it has a large large amount of insider holding.  Take a look; I don't have a crystal ball exactly, but I've stocked up. 

    I would think this one is ~2 weeks from popping if we expect good news at the annual meeting on June 17th.  If not at the meeting, then in Aug during Q2 reporting when first sales start to hit the public.
    Bullish
  • R
    Royco
    18 days ago...”“there's something happenin' here...Buffalo Springfield is prescient ...
    “For What It's Worth”!”
    Today it comes to fruition...and maybe, just maybe there are suitors gathering interest, and/or the meat of this company is nearing its medical endpoints.
    Gltlongs
  • W
    Walter
    The following is from the Q2 earnings transcript... an interesting licence deal is on the way for the Vet product!

    "Clearly, I’m new to the Volition team, but I believe it is no secret that Volition does not currently have the ambition to assemble its own large scale sales and marketing teams, but rather to focus our skill set and knowhow on scientific breakthroughs and intellectual property development, and to drive the revenues by licensing our patented technologies to large companies already placed within the relevant marketplace.

    And so a great deal of my time together with our Chief Commercial Officer, Gael Forterre and other talented members of the Volition team has been spent identifying, vetting, working with and negotiating with several potential licensing partners around the world.

    We are not at the finish line just yet, and I clearly cannot disclose too much given the very active negotiations, but we have a lot of good folks around the table and we are certainly at the business end of negotiation with a number of prospective partners."
  • X
    XTRADER
    lonely on this board, but in another few weeks, hopefully others will join...if test results are good, we are off to $7
  • R
    Raf
    New viedeo from volitionrx on your youtube chanel. I hope this is a positive sign.
    https://youtu.be/sCHMjxwgO-w
    Dr. Jake Micallef, Chief Scientific Officer of Volition, provides a thorough explanation of the science and technology behind our tests. He also goes onto ex...
    Dr. Jake Micallef, Chief Scientific Officer of Volition, provides a thorough explanation of the science and technology behind our tests. He also goes onto ex...
    www.youtube.com
  • G
    Gcm
    One of the directors bought 50,000 shares. If that was an open market purchase, that's good news.
  • P
    PSea
    Got on conference call late. They sure sound bullish on the call.
  • A
    AJ111
    The reason for the stock being up is because Paul Mamphilly has recommended the stock in his "Extreme Fortune" portfolio. Be aware that by next week the stock will be back in the $4s. So dont rush to buy. His Extreme Fortune stocks are all like this. They surge on the recommendation only to deflate a few days later back to where they were or lower. And this is what he is saying about the stock:

    VolitionRX is a multinational life sciences company that’s leading the pack in developing simple, easy-to-use blood-based cancer tests to accurately diagnose a wide variety of cancers.

    Like our previous precision medicine winners Foundation Medicine and Genomic Health, VolitionRX is a large part of the massive biotech market.

    Right now, this company has several large ongoing clinical studies with over 75,000 samples, bringing treatments for blood cancers even closer to the mass market.

    VolitionRX’s research is also looking into treatments for lung, prostate and colorectal cancers, making its stock all the more valuable as its research becomes more mainstream.

    VolitionRX’s stock hits the golden trio of GoingUpness: InDemandness, Insiderness and ValueAbility.

    Right now, VolitionRX is trading 213% above its 52-week low, meaning that the demand for its stock is on an impressive upward trend.

    Recently, the company’s director scooped up a total of 420,000 shares in June and August, which totaled $1.4 million.

    But the most promising figure that I’ve found is that VolitionRX’s revenue is on track to skyrocket to $114 million by 2023.

    That’s a 114,400% increase in just four years!

    I want you to be able to ride VolitionRX’s revenue surge as it gains more and more traction from its precision blood cancer treatments, so I recommend buying into this stock today.
  • P
    PSea
    Ummm. This might be where I say HOLY MOLY!

    https://fintel.io/doc/sec/1761462/000107878219000008/sc13g010319_sc13g.htm

    Read the paragraph near the bottom which helps explain the full picture. What I can't tell is how long these guys have been accumulating. Did this all just happen recently or has this been slow accumulation?

    Either way, it's a HUGE POSITION. Was anyone else aware of this or is this completely new news?
    VNRX / VolitionRX Ltd / Cotterford Co Ltd - SCHEDULE 13G (Passive Investment) - January 03, 2019 - Fintel.io
    fintel.io
  • M
    Mike
    This is another Mike, the one from the EXAS board. I've also invested here and look forward to the upcoming news. Not concerned with early Feb comment and a good portfolio supplement to EXAS. GLTA!
  • P
    PSea
    As of the 15th they were still waiting for the data per this bloomberg radio interview. I can't take credit for finding this. Another forum's member found it.

    https://assets.bwbx.io/av/users/iqjWHBFdfxIU/vJOeC1xgPDFQ/v2.mp3
  • X
    XTRADER
    Once they announce results next month, we will see $5+
  • P
    PSea
    Anyone watching ITUS?
  • A
    Anonymous
    Early February clearly means something else to the PR department.
Advertisement
Advertisement